Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Bevacizumab +/- CDX-1140 in Recurrent Ovarian Cancer
NCT05231122Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CDX-1140 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Roswell Park Comprehensive Cancer Center. Started Mar 2024; status: recruiting.
02
Drugs
CDX-1140
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05231122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231122.